🔍

SANOFICONR - Sanofi Consumer

📊 NSE: SANOFICONR 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/14/2025 12:48

📢 Recent Corporate Announcements

Sanofi Consumer Healthcare Q1 PAT Rises 35.6% YoY to ₹67.8 Cr; Revenue Up 32.8%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 28 Apr 2026, 04:28 PM

Sanofi Consumer Healthcare India reported a strong year-on-year performance for the quarter ended March 31, 2026, with net profit rising 35.6% to ₹678 million. Revenue from operations grew 32.8% YoY to ₹2,292 million, primarily driven by a 15.5% growth in domestic sales following the successful relaunch of key brands like Allegra and Combiflam. While YoY growth is robust, revenue saw a sequential decline of 8.7% compared to the December 2025 quarter. The company maintains healthy margins with Profit Before Tax (PBT) reaching ₹907 million.

Revenue from operations increased 32.8% YoY to ₹2,292 million from ₹1,726 million.
Net Profit (PAT) grew 35.6% YoY to ₹678 million compared to ₹500 million in the year-ago period.
Domestic sales grew by 15.5% YoY, aided by the relaunch of Allegra Suspension, Combiflam Suspension, and Depura Kids.
Export sales witnessed a significant jump of 144.4% YoY, though on a lower base.
Earnings Per Share (EPS) improved to ₹29.44 from ₹21.69 in the same quarter last year.

💡 Investors should view the strong YoY growth as a sign of successful brand recovery following previous product recalls. The stock remains a watch for steady growth in the consumer healthcare segment, though sequential revenue dips should be monitored for seasonality.

Sanofi Consumer Healthcare Shareholders Approve Key RPTs and MD Remuneration

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 23 Apr 2026, 07:16 PM

Sanofi Consumer Healthcare India Limited (SANOFICONR) has announced the successful passage of four key resolutions via postal ballot, all receiving over 99.9% shareholder approval. The resolutions include material related party transactions with Opella Healthcare entities and the establishment of remuneration limits for Non-Executive Directors. Crucially, shareholders approved an amendment to Managing Director Himanshu Bakshi's remuneration to enable his participation in the company's incentive plan. These approvals facilitate operational continuity and align leadership incentives with business performance.

Material related party transactions with Opella Healthcare India and International SAS approved with over 99.94% votes in favor.
Remuneration limits for Non-Executive Directors passed with a near-unanimous 99.99% majority.
Amendment to MD Himanshu Bakshi's remuneration for incentive plan participation approved by 99.98% of voters.
The voting process involved 50,742 shareholders on record as of March 20, 2026.

💡 Investors should take note of the strong shareholder support for management's compensation structure and operational agreements. The alignment of the Managing Director's pay with incentive plans is a positive governance signal for long-term performance.

Sanofi Consumer Healthcare Submits SEBI Reg 74(5) Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 03:53 PM

Sanofi Consumer Healthcare India Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2026. The certificate, issued by Registrar MUFG Intime India Private Limited, confirms that all securities received for dematerialization were processed and confirmed to the depositories within the prescribed timelines. It also verifies that physical share certificates were mutilated and cancelled after due verification. This is a standard procedural filing required for all listed companies in India to ensure the integrity of the dematerialization process.

Compliance certificate submitted for the quarter ended March 31, 2026.
Registrar MUFG Intime India Private Limited confirmed processing of dematerialization requests.
Verification that physical certificates were mutilated and cancelled as per SEBI guidelines.
Confirmation that the register of members was updated with depository names within mandated timelines.

💡 No action is required as this is a routine administrative filing confirming regulatory compliance. Investors should continue to monitor the company's operational performance and upcoming financial results.

Sanofi Consumer Healthcare Reports 21% Revenue Growth and 62.5% ROCE in First Investor Meet

🟢 POSITIVE ⭐ 8/10

MANAGEMENT 📅 27 Mar 2026, 12:11 PM

Sanofi Consumer Healthcare India Limited (SCHIL) detailed its strategic transition to a standalone 'Fast Moving Consumer Health' entity following its demerger. For FY2025, the company reported a turnover of approximately ₹880 crore, representing a 21% revenue growth and a 33% increase in PAT. Management is aggressively pivoting from a prescription-only model to a brand-led consumer model, increasing advertising and promotion spends from low single digits to mid-teens. The company maintains a high-quality balance sheet with an operating profit margin of 37% and a robust ROCE of 62.5%.

Achieved ₹880 crore turnover with a 33% year-on-year increase in Profit After Tax (PAT).
Reported a high Return on Capital Employed (ROCE) of 62.5% and operating profit margins of 37%.
Increased brand investment (A&P) to mid-teen percentages to drive self-choice consumer growth.
Core brands like Avil, Allegra, and Combiflam maintain top 5 positions in their respective categories.
Successfully completed product relaunches following precautionary quality recalls, restoring market leadership.

💡 Investors should monitor the company's ability to sustain high margins while scaling marketing spends in the competitive consumer health space. The high ROCE and strong brand legacy make it a premium play in the Indian healthcare sector.

Sanofi Consumer Healthcare India Releases Recording of March 24 Institutional Investor Meet

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 26 Mar 2026, 12:07 PM

Sanofi Consumer Healthcare India Limited (SANOFICONR) has officially released the video recording of its Institutional Investor Meet held on March 24, 2026. This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations, 2015, aimed at ensuring transparency for all stakeholders. The recording allows investors to review management's commentary on the company's business strategy and operational outlook. Access to such meetings is particularly relevant for this entity following its demerger and independent listing.

Institutional Investor Meet was successfully conducted on March 24, 2026
Video recording made available on the company's official website on March 26, 2026
Compliance filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
Provides a platform for shareholders to understand management's strategic vision for the consumer healthcare portfolio

💡 Investors should review the recording to gain deeper insights into the company's growth strategy and brand performance. This is a valuable resource for fundamental analysis of the newly listed consumer healthcare business.

Sanofi Consumer Healthcare India to Close Trading Window from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Mar 2026, 06:16 PM

Sanofi Consumer Healthcare India Limited has announced the closure of its trading window for all designated persons starting April 1, 2026. This action is taken in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results for the quarter ending March 31, 2026. The window will remain closed until 48 hours after the results are officially announced to the stock exchanges. This is a standard regulatory procedure for listed companies in India.

Trading window closure begins on April 1, 2026
Closure is for the purpose of declaring Unaudited Standalone Financial Results for the quarter ended March 31, 2026
The window will reopen 48 hours after the results are communicated to BSE and NSE

💡 No action is required as this is a routine regulatory filing. Investors should await the announcement of the actual board meeting date for the Q4 results.

Sanofi Consumer Healthcare Reports 33% PAT Growth and Outlines 2X Reach Strategy

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 24 Mar 2026, 03:36 PM

Sanofi Consumer Healthcare India Limited (SCHIL) reported a strong FY2025 with revenue growing 21% to ₹8,784 million and PAT increasing by 33%. The company is pivoting to a Fast Moving Consumer Healthcare (FMCH) model, aiming to double its doctor reach and direct retail coverage. With a high ROCE of 62.5% and market-leading brands like Avil and Allegra, the management is focusing on digital-first demand generation and FMCG-style talent acquisition. The strategy emphasizes scaling consumer engagement to a 60 million multi-media reach to capture high headroom in the Allergy, Pain, and Vitamin D categories.

Revenue from operations grew 21% YoY to ₹8,784 million with a 36.7% operating profit margin.
Profit After Tax (PAT) increased by 33% YoY, supported by a robust 62.5% Return on Capital Employed (ROCE).
Company plans to double (2X) its doctor reach and direct retail coverage to improve market access.
Maintains strong brand equity with Avil ranked #1 in volume and Allegra ranked #3 in value within their categories.
Digital-first approach targeting 30% demand generation and a 60 million multi-media reach.

💡 Investors should note the company's high capital efficiency (62.5% ROCE) and its aggressive transition toward a retail-heavy FMCH model. The stock remains a strong play on the increasing consumer self-medication trend in India, though execution of the 2X reach target will be the key metric to watch.

Sanofi Consumer Healthcare Seeks Approval for ₹4,614 Million Related Party Transactions

🟡 NEUTRAL ⭐ 7/10

REGULATORY 📅 23 Mar 2026, 07:50 PM

Sanofi Consumer Healthcare India Limited has issued a postal ballot notice seeking shareholder approval for material related party transactions (RPTs) for the 2026 calendar year. The company is proposing a transaction limit of ₹1,200 million with Opella Healthcare India and ₹3,414 million with Opella Healthcare International SAS. Additionally, the ballot covers the approval of remuneration for Non-Executive Directors up to 1% of net profits and an amendment to the Managing Director's incentive plan. The e-voting period runs from March 24, 2026, to April 22, 2026.

Proposed RPT limit of ₹1,200 million with Opella Healthcare India Private Limited for the year ending December 2026.
Proposed RPT limit of ₹3,414 million with Opella Healthcare International SAS for the year ending December 2026.
Approval sought for Non-Executive Director commissions not exceeding 1% of annual Net Profits.
Amendment to Managing Director Himanshu Bakshi's remuneration terms to enable participation in the company's Incentive Plan.
Voting results to be announced on or before April 24, 2026, following the month-long e-voting window.

💡 Investors should monitor the outcome of the vote to ensure that the significant related party transactions are conducted at arm's length and do not adversely affect minority interests. The scale of these transactions reflects the company's operational integration with the global Opella/Sanofi structure.

Sanofi Consumer Healthcare India Schedules Institutional Investors Meet for March 24, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 19 Mar 2026, 05:24 PM

Sanofi Consumer Healthcare India Limited (SANOFICONR) has announced a physical group interaction with institutional investors scheduled for March 24, 2026, in Mumbai. This meeting is a standard regulatory disclosure under SEBI Listing Regulations to facilitate management interaction with the investment community. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this session. Such meetings are typical for newly listed or demerged entities to establish rapport with institutional stakeholders.

Institutional Investors Meet scheduled for Tuesday, March 24, 2026.
The interaction will be a physical group meeting held in Mumbai.
Management representatives will lead the discussion on general business updates.
Company confirms compliance with SEBI Regulation 30 regarding non-disclosure of UPSI.

💡 No immediate action is required; however, investors should monitor the exchange filings after March 24 for any investor presentations or transcripts that may provide insights into the company's growth strategy.

Sanofi Consumer Healthcare Designates Nupur Gurbaxani and Viral Shah as Senior Management

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 25 Feb 2026, 08:57 PM

Sanofi Consumer Healthcare India Limited has elevated two key directors, Ms. Nupur Gurbaxani and Mr. Viral Shah, to Senior Management Personnel (SMP) status effective February 25, 2026. Ms. Gurbaxani, Director of Brand & Innovation, brings 18 years of experience from firms like Novartis and Abbott to lead brand transformation. Mr. Shah, Director of External Manufacturing, has 20 years of industry experience and is tasked with strengthening 'Make in India' initiatives and export growth. These designations signal a focus on strengthening the leadership team to drive digital-first marketing and manufacturing infrastructure.

Ms. Nupur Gurbaxani (Director, Brand & Innovation) designated as SMP with 18+ years of industry experience.
Mr. Viral Shah (Director, External Manufacturing) designated as SMP with 20+ years of experience in manufacturing and exports.
Designations are effective from February 25, 2026, following Board and NRC recommendations.
Strategic focus placed on 'Make in India' infrastructure and digital-first brand penetration turnaround.

💡 Investors should view this as a routine governance update strengthening the leadership tier. Monitor the company's upcoming quarterly results for improvements in brand penetration and manufacturing efficiencies attributed to these leaders.

Sanofi Consumer Healthcare Designates Two Directors as Senior Management Personnel

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 25 Feb 2026, 08:53 PM

Sanofi Consumer Healthcare India Limited has designated Ms. Nupur Gurbaxani and Mr. Viral Shah as Senior Management Personnel effective February 25, 2026. Ms. Gurbaxani, Director of Brand & Innovation, brings over 18 years of experience from firms like Novartis and Abbott to drive brand penetration. Mr. Shah, Director of External Manufacturing, has over 20 years of experience and focuses on "Make in India" initiatives and export growth. These designations formalize the leadership roles of key executives who joined the company in mid-2024.

Ms. Nupur Gurbaxani (18+ years experience) designated as Senior Management Personnel
Mr. Viral Shah (20+ years experience) designated as Senior Management Personnel
Designations are effective from February 25, 2026, following a Board meeting
Leadership focus remains on brand transformation, digital-first strategy, and manufacturing infrastructure

💡 No immediate action is required as these are internal designations of existing directors. Monitor the impact of their leadership on brand growth and manufacturing efficiency in future earnings reports.

Sanofi Consumer Healthcare Q4 Profit Jumps 50% to ₹665 MN; ₹75 Dividend Declared

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 25 Feb 2026, 08:30 PM

Sanofi Consumer Healthcare India (SCHIL) reported a robust Q4 performance with revenue growing 47% YoY to ₹2,510 million and net profit surging 50% to ₹665 million. For the full year 2025, the company achieved a 21% revenue growth and a 33% increase in PAT, reaching ₹2,401 million. The board has recommended a substantial dividend of ₹75 per share, reflecting strong cash generation. Growth was primarily driven by a 23% rise in domestic sales and the successful relaunch of recalled products.

Q4 Revenue grew 47% YoY to ₹2,510 million, while Net Profit rose 50% to ₹665 million.
Full-year FY25 PAT increased by 33% to ₹2,401 million on total revenue of ₹8,784 million.
Declared a significant dividend of ₹75 per share for the financial year ended December 31, 2025.
Domestic sales grew by 23% in Q4, supported by brand relaunches and core portfolio strength.
Export sales for Q4 grew 9.3x and full-year exports grew 158%, albeit from a low base.

💡 The strong double-digit growth and high dividend payout indicate successful post-demerger stabilization and operational efficiency. Investors may consider this a positive signal for long-term value in the consumer healthcare space, given the strength of brands like Combiflam and Allegra.

Sanofi Consumer Healthcare FY25 Net Profit Jumps 33% to ₹240 Cr; Recommends ₹75 Dividend

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 25 Feb 2026, 07:57 PM

Sanofi Consumer Healthcare India reported a strong financial performance for the year ended December 31, 2025, with annual revenue growing 21% to ₹8,784 million. Net profit for the full year surged by 32.6% to ₹2,401 million, driven by robust operational performance and higher other income. The Board has recommended a substantial final dividend of ₹75 per equity share, highlighting strong cash flow generation. Quarterly growth was even more pronounced, with Q4 revenue increasing 47% year-on-year to ₹2,510 million.

Full-year FY25 revenue increased 21.2% to ₹8,784 million from ₹7,245 million in FY24.
Net profit for FY25 rose to ₹2,401 million, up from ₹1,810 million in the previous year.
Board recommended a final dividend of ₹75 per equity share (750% of face value).
Earnings Per Share (EPS) for FY25 improved significantly to ₹104.27 from ₹78.59.
Q4 FY25 net profit stood at ₹665 million, a 50% increase compared to ₹443 million in Q4 FY24.

💡 Investors should view these results positively given the strong double-digit growth in both top-line and bottom-line, coupled with a high dividend payout. The stock remains attractive for those seeking a combination of growth in the consumer healthcare space and high yield.

Sanofi Consumer Healthcare Recommends Rs 75 Dividend; FY25 Net Profit Rises 33%

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 25 Feb 2026, 07:37 PM

Sanofi Consumer Healthcare India has recommended a final dividend of Rs. 75 per share for the financial year ended December 31, 2025. The company reported a strong financial performance with annual revenue growing 21% to Rs. 8,784 million. Net profit for the full year increased significantly by 33% to Rs. 2,401 million compared to the previous year. The quarterly performance was also robust, with Q4 profit rising to Rs. 665 million from Rs. 443 million year-on-year.

Recommended a final dividend of Rs. 75 per equity share of face value Rs. 10.
Annual Revenue from Operations grew 21.2% YoY to Rs. 8,784 million in FY25.
Net Profit for the full year surged 32.7% to Rs. 2,401 million from Rs. 1,810 million.
Earnings Per Share (EPS) increased to Rs. 104.27 from Rs. 78.59 in the previous year.
Q4 FY25 revenue stood at Rs. 2,510 million, a 47% increase over Q4 FY24.

💡 Investors should note the strong growth trajectory and the substantial dividend payout which reflects robust cash flows. The stock is likely to be viewed favorably by both growth and income-seeking investors due to the earnings outperformance.

Sanofi Consumer Healthcare FY25 Net Profit Jumps 33% to ₹2,401 Mn; ₹75/Share Dividend Declared

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 25 Feb 2026, 07:11 PM

Sanofi Consumer Healthcare India reported a strong performance for the financial year ended December 31, 2025, with annual revenue growing 21% to ₹8,784 million. Net profit for the full year increased significantly by 32.6% to ₹2,401 million, supported by improved operational efficiencies. The Board has recommended a substantial final dividend of ₹75 per share, reflecting a high payout ratio and strong cash position. Quarterly performance was also robust, with Q4 revenue up 47% year-on-year to ₹2,510 million.

Full-year FY25 Revenue from Operations rose 21.2% YoY to ₹8,784 million versus ₹7,245 million.
Net Profit for FY25 increased to ₹2,401 million from ₹1,810 million in the previous year.
Recommended a final dividend of ₹75 per equity share of face value ₹10 for the financial year.
Q4 FY25 Net Profit grew 50% YoY to ₹665 million compared to ₹443 million in Q4 FY24.
Earnings Per Share (EPS) improved significantly to ₹104.27 for FY25 from ₹78.59 in FY24.

💡 Investors should react positively to the strong double-digit growth in both revenue and profitability alongside a very generous dividend payout. The company's transition and focus on consumer healthcare appear to be yielding high margins and robust cash flows.

View All SANOFICONR Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single business segment, 'Pharmaceutical Business'. For Q3 2025, revenue was INR 233.9 Cr, representing a 46% YoY growth. For the nine months ended September 2025, revenue reached INR 627.4 Cr, up 13% YoY.

Geographic Revenue Split

In Q3 2025, Domestic sales grew by 20% YoY, while Export sales grew by 1031% YoY on a low base. For the nine-month period, Domestic sales grew by 1% and Export sales grew by 96% YoY.

Profitability Margins

For CY 2024, the Operating Profit Margin was 35% (down from 39% in 2023) and the Net Profit Margin was 25% (down from 30% in 2023). Q3 2025 Net Profit was INR 62.9 Cr, a 40% increase YoY.

EBITDA Margin

In CY 2024, the company achieved an EBITDA of INR 255.2 Cr with an EBITDA margin of 35%. Core profitability remains strong despite a slight margin compression compared to the restated 2023 figures.

Credit Rating & Borrowing

Not disclosed in available documents; however, the company reported a Debt-Equity ratio of 'NA', indicating a debt-free balance sheet.

⚙️ Operational Drivers

Operational analysis data not yet available for this company.

📈 Strategic Growth

Expected Growth Rate

13%

Growth Strategy

Growth is driven by the 'India for India' strategy, leveraging global Opella expertise to implement local Consumer Healthcare (CHC) strategies. Key drivers include the successful re-establishment of voluntarily recalled products and active engagement with regulators to shape OTC regulations in India. The transition to a standalone entity under CD&R ownership (50% stake) aims to enhance local agility and decision-making.

Products & Services

Consumer healthcare and pharmaceutical products (OTC medicines).

New Products/Services

The company focused on re-establishing voluntarily recalled products within the year, which have successfully regained market presence.

Market Expansion

Focus on the Indian domestic market, which saw 20% growth in Q3 2025, and expanding export reach from a low base.

Strategic Alliances

The company demerged from Sanofi India Limited in June 2024. Globally, Sanofi sold a 50% controlling stake in the parent Opella group to Clayton, Dubilier & Rice (CD&R) in April 2025.

🌍 External Factors

Industry Trends

The Indian consumer healthcare sector is shifting toward standalone specialized entities. Regulatory evolution in OTC frameworks is a key trend, with the company actively participating in shaping these norms to increase self-care accessibility and market reach.

Competitive Moat

The moat is derived from global science-based self-care expertise via the Opella group and a resilient brand portfolio that successfully recovered from product recalls. The 'India for India' strategy provides local agility while maintaining global quality standards.

Consumer Behavior

Increasing consumer demand for simpler, more accessible, and more effective self-care solutions.

⚖️ Regulatory & Governance

Industry Regulations

The company is actively engaged with regulatory authorities to help shape Over-the-Counter (OTC) regulations in India, which is critical for its standalone consumer healthcare strategy.

Legal Contingencies

No material fines, penalties, or settlement amounts were paid to regulators or law enforcement agencies in CY 2024.

⚠️ Risk Analysis

Key Uncertainties

Key risks include regulatory shifts in OTC drug classifications and potential product quality issues or recalls, which can disrupt market presence for up to a year.